Researchers from the University of Reading and the Technical University of Denmark demonstrated that mRNA encapsulated in lipid nanoparticles can induce protective antibodies in muscle and reduce Bothrops asper venom–induced damage in vitro and in mice. A single intramuscular mRNA dose produced antibodies within 12–24 hours and prevented muscle injury when administered up to 48 hours before venom exposure. The preclinical work suggests mRNA platforms developed for COVID‑19 could be repurposed to address local toxin‑mediated injuries that conventional antivenoms struggle to neutralize at bite sites. Companies working on mRNA delivery and emergency therapeutics may explore rapid‑response prophylactics or adjuncts to antivenom treatment.